GSK Reports Results of Nucala (mepolizumab) in P-III Study for Hypereosinophilic Syndrome

 GSK Reports Results of Nucala (mepolizumab) in P-III Study for Hypereosinophilic Syndrome

Shots:

  • The P-III study involve assessing Nucala (300mg, q4w, SC) vs PBO in 108 adolescent and adult patients with severe HES for 32wks.
  • The P-III study results: met its 1EPs i.e, reduction in flares with 50% fewer patients experiencing HES flare (56% vs 28%). 2EPs: 66% lower risk of first HES flare; 66% reduction in the annualized rate of HES flares; improvement in fatigue score; safety results were consistent with the known profile of Nucala
  • Nucala is mAb targeting IL-5, first treatment demonstrating a reduction in flares in HES and has received the FDA & EMA’s ODD to treat HES with its anticipated regulatory submission in 2020

Click here to­ read full press release/ article | Ref: GSK | Image: Nypost

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post